Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Kansas Cancer Center awarded two Indian American doctors professorships.

2.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

3.

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

4.

Breast cancer: A new target to eliminate dormant cells before they wake

5.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot